Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
17.04 USD
↗ 0.18 (1.07%)AT CLOSE (03:59 PM EDT)
17.05
↗ 0.01 (0.05%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
17.05
↗ 0.01 (0.05%)
🔴Market: CLOSED

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $17.03. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Strong Buy" respectively. Notable factors include a robust Altman Z-Score, a strong Piotroski F-Score of 7/9, exceptional Return on Equity (51.1%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Oct 26, 2026.

Open?$16.98
High?$17.16
Low?$16.92
Prev. Close?$16.86
Volume?794.7K
Avg. Volume?828.1K
VWAP?$17.00
Rel. Volume?0.96x
Bid / Ask
Bid?$14.44 × 100
Ask?$19.38 × 100
Spread?$4.94
Midpoint?$16.91
Valuation & Ratios
Market Cap?2.2B
Shares Out?133.1M
Float?107.3M
Float %?80.7%
P/E Ratio?7.14
P/B Ratio?3.65
EPS?$2.36
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookStrong Buy
Strong SellNeutralStrong Buy
F-Score?
88
Z-Score?
100
Momentum?
90
Short Sent.?
34
Piotroski F-Score?7/9Strong
Altman Z-Score?8.20Safe
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?7.25%Elevated
Short Interest?7.8M
Days to Cover?9.0
Free Float107.3M
Avg Daily Volume868.5K
Settlement Date2026-10-15
Financial Health
Current Ratio?5.42Strong
Quick Ratio?4.97Strong
Cash Ratio?1.80Strong
Debt/Equity?0.10Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
Peers
100
S&P
97
7.1CHEAP▾
P/B?
Peers
100
S&P
48
3.65FAIR▾
P/S?
Peers
100
S&P
16
7.20HIGH▾
P/FCF?
Peers
100
S&P
81
12.8CHEAP▾
EV/EBITDA?
Peers
100
S&P
59
13.6FAIR▾
EV/Sales?
Peers
100
S&P
21
6.82HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
51.1%STRONG▾
ROA?
Peers
50
S&P
97
39.7%STRONG▾
Cash Flow & Enterprise
FCF?$175.1M
Enterprise Value?$2.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist